SummaryInflammaging plays an important role in most ageârelated diseases. However, the mechanism of inflammaging is largely unknown, and therapeutic control of inflammaging is challenging. Human alphaâ1 antitrypsin (hAAT) has immuneâregulatory, antiâinflammatory, and cytoprotective properties as demonstrated in several disease models including type 1 diabetes, arthritis, lupus, osteoporosis, and stroke. To test the potential antiâinflammaging effect of hAAT, we generated transgenic Drosophila lines expressing hAAT. Surprisingly, the lifespan of hAATâexpressing lines was significantly longer than that of genetically matched controls. To understand the mechanism underlying the antiâaging effect of hAAT, we monitored the expression of agingâassociated genes and found that agingâinduced expressions of Relish (NFâÄžB orthologue) and Diptericin were significantly lower in hAAT lines than in control lines. RNAâseq analysis revealed that innate immunity genes regulated by NFâkB were significantly and specifically inhibited in hAAT transgenic Drosophila lines. To confirm this antiâinflammaging effect in human cells, we treated Xârayâinduced senescence cells with hAAT and showed that hAAT treatment significantly decreased the expression and maturation of ILâ6 and ILâ8, two major factors of senescenceâassociated secretory phenotype. Consistent with results from Drosophila,
RNAâseq analysis also showed that hAAT treatment significantly inhibited inflammation related genes and pathways. Together, our results demonstrated that hAAT significantly inhibited inflammaging in both Drosophila and human cell models. As hAAT is a FDAâapproved drug with a confirmed safety profile, this novel therapeutic potential may make hAAT a promising candidate to combat aging and agingârelated diseases.